Last reviewed · How we verify

Phase 1, Open-Label, Randomized, Single-Dose, 5-Way Crossover Pilot Bioavailability Study Comparing Eletriptan Oral Disintegrating Tablet Formulations A And B Administered With Or Without Water To Relpax® Commercial Tablets Administered With Water

NCT00871806 Phase 1 COMPLETED

The study will evaluate whether the blood concentrations of eletriptan administered using two test formulations of oral disintegrating tablets are comparable to those observed with the standard commercial tablet.

Details

Lead sponsorPfizer's Upjohn has merged with Mylan to form Viatris Inc.
PhasePhase 1
StatusCOMPLETED
Enrolment20
Start date2009-04
Completion2009-04

Conditions

Interventions

Primary outcomes

Countries

Singapore